E board review in Breast Cancer February 2008

Article

E board review in Breast Cancer February 2008

 

 

E-Board Review in Oncology:
Breast Cancer

The board review on breast cancer that follows is designed to help you discern the critical issues relating to the treatment of breast cancer. The subjects covered in this program represent scenarios clinicians face each day and reflect cutting-edge findings reported at major medical meetings. The hope is that the 36 questions and answers in the review will direct your focus in the ever-changing scope of options for breast cancer patients and lead to a higher quality of care and prolonged survival for them. This review should also serve as a valuable resource to help prepare you for the Medical Oncology Board Certification Examination.

After you work through the questions and answers, you can print a PDF of the entire program for future reference-instructions for doing so will appear on your screen after you complete the 36 questions.

In addition, you can earn 3 CME credits after completion of the program. Click on Earn Continuing Medical Education Credit and follow the instructions found there.

We hope you will find this review both interesting and informative-as both a resource for improving patient care and a study guide.

Editor:

Matthew J. Ellis, MB, BChir, PhD, FRCP
Director, Breast Cancer Program
Anheuser Busch Tenured
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

Steven M. Sorscher, MD
Assistant Professor of Medicine
Division of Oncology
Director, Siteman Cancer Center, West Country
Washington University School of Medicine
St. Louis, Missouri

Cynthia X. Ma, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Washington University
School of Medicine
St. Louis, Missouri

 

Recent Videos
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content